Benefits and limitations of incretin-based therapies and sodium-glucose transporter 2 inhibitors on diabetic kidney disease
Journal
Journal of Internal Medicine of Taiwan
Journal Volume
27
Journal Issue
5
Pages
248-260
Date Issued
2016
Author(s)
Abstract
Diabetic kidney disease (DKD) is one of major causes of mortality in patients with diabetes mellitus and is also the leading cause of end-stage renal disease in the world. DKD is a clinical syndrome, characterized by persistent albuminuria (daily urine protein loss >300 minigram), declined glomerular filtration rate, arterial pressure elevation, increase cardiovascular events and mortality rate. In Taiwan, the major group of incidental dialysis is patients with diabetes mellitus. The number of receiving dialysis patients with diabetes mellitus is still increasing up to date. Besides, patients with diabetes and receiving dialysis have higher mortality than those without diabetes. Risk factors of DKD include ethics, sex, albuminuria, hyperglycemia, hypertension, dyslipidemia, hypercholesterolemia, smoking, gene susceptibility, etc. More recent researches have proved that adequate blood sugar control prevents from occurrence of complications and relieve progression of DKD. Although there are many kinds of blood glucose-lowering drugs in the past decades, the number of people achieving goals of blood sugar control is still limited. Moreover, the side effects of these drugs, such as hypoglycemia and weight gain restrict the blood glucose control. Hence, novel blood glucose-lowering drugs and options were developed in recent years for prevention of progressive nephropathy. This article emphasizes on benefits and limitations of incretin-based therapies and sodium-glucose transporter 2 inhibitors by reviewing current animal, laboratory and human researches.
SDGs
Publisher
Society of Internal Medicine of Taiwan
Type
journal article